Centene Management
Management Kriterienprüfungen 3/4
Centene CEO ist Sarah London , ernannt in Mar 2022, hat eine Amtszeit von 4.25 Jahren. Die jährliche Gesamtvergütung beträgt $19.51M , bestehend aus 7.6% Gehalt und 92.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.061% der Aktien des Unternehmens, im Wert von $18.83M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 4.4 Jahre.
Wichtige Informationen
Sarah London
Geschäftsführender
US$19.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 7.55% |
| Amtszeit als Geschäftsführer | 4.3yrs |
| Eigentum des Geschäftsführers | 0.06% |
| Durchschnittliche Amtszeit des Managements | 4.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.4yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • Jun 19
Centene (CNC) Stock Could Be 11% Overvalued After Employee Buyout Offer
Centene (CNC) stock is in focus after the company moved to offer voluntary buyouts to most employees, a cost reduction step tied to weaker health plan membership, especially in Affordable Care Act marketplace products. See our latest analysis for Centene. Despite the recent buyout announcement and a sharp pullback of nearly 4% on the day it was reported, Centene’s share price has a 90 day share price return of 77.38% and a 1 year total shareholder return of 10.64%. However, 3 and 5 year total...
Narrativ-Update • Jun 15
CNC: Medicaid Margin Recovery And Stable Policy Backdrop Will Support Future Earnings
Centene's analyst fair value estimate has been updated from $60.51 to $80.00. This reflects a broad series of higher Street price targets as analysts highlight a more stable managed care policy backdrop, margin recovery potential, and evidence of muted medical cost trends and softer utilization across the sector.Seeking Alpha • Jun 12
Centene's Impressive Comeback Still Holds Up
Summary Centene delivered a strong Q1, raising 2026 adjusted EPS outlook above $3.40 and driving a 90% stock gain since my last Buy call. CNC's Medicaid revenue and margin restoration efforts are succeeding, with Medicaid HBR down 50 bps and SG&A improving to 7.6% of revenue. Medicare mix is shifting toward PDP with stable margins, while Marketplace faces an $8B revenue headwind in 2026 from expiring subsidies, already reflected in guidance. I maintain a Buy rating, as operational improvements, capital discipline, and reset guidance support further upside, though headline and policy risks remain. Read the full article on Seeking Alpha
Narrativ-Update • Jun 01
CNC: Medicaid Margin Recovery Expectations Will Eventually Disappoint Current Optimism
Narrative Update Overview The analyst fair value estimate for Centene has moved from $32.00 to $40.00 as analysts factor in improving margin recovery expectations across government programs, steadier commercial trends, and a modestly higher assumed future P/E multiple that aligns with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Centene has shifted toward a more constructive stance, with multiple firms lifting price targets and, in some cases, upgrading ratings.
Narrativ-Update • May 16
CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty
Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.Narrativ-Update • Apr 29
CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside
Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.Narrativ-Update • Apr 15
CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power
Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.Narrativ-Update • Apr 01
CNC: Government Program Margins In 2026 Will Support Future Earnings Power
Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.Narrativ-Update • Mar 18
CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power
Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.Narrativ-Update • Mar 04
CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance
Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.Narrativ-Update • Feb 17
CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook
Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.Narrativ-Update • Feb 03
CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery
Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.Narrativ-Update • Jan 20
CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power
Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.Narrativ-Update • Jan 06
CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook
Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.Narrativ-Update • Dec 19
CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead
Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.Narrativ-Update • Dec 05
CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds
Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.Narrativ-Update • Nov 21
CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside
Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.Narrativ-Update • Nov 06
CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects
Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.Narrativ-Update • Oct 22
Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds
Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.Narrativ-Update • Oct 08
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.Narrativ-Update • Sep 19
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.Analyseartikel • Sep 12
Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...Narrativ-Update • Sep 04
Medicaid And Medicare Advantage Will Expand Health Care Access
Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.Analyseartikel • Jul 03
Why Investors Shouldn't Be Surprised By Centene Corporation's (NYSE:CNC) 38% Share Price Plunge
Unfortunately for some shareholders, the Centene Corporation ( NYSE:CNC ) share price has dived 38% in the last thirty...Seeking Alpha • Mar 26
Centene: A Leader In Government-Sponsored Insurance And Its Prospects
Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Centene Corporation Is Resilient And Will Thrive
Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking AlphaSeeking Alpha • Jan 02
Centene: Attractive Risk-Reward For A Growing Company At A Value Price
Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024
Summary Centene, a leading health insurer, shows strong fundamentals and growth despite sector challenges, making it a "Buy" at a target price of $70/share. The company’s 2Q24 results indicate robust earnings growth and increasing membership, contrasting with peers like Humana, which face significant declines. Centene's valuation at $61/share with a P/E of 9x is attractive, projecting a potential 27.17% annualized upside until 2026. Despite lacking a dividend, Centene's stability and growth prospects in government programs and managed healthcare segments justify a conservative investment approach. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$6b |
| Dec 31 2025 | US$20m | US$1m | -US$7b |
| Sep 30 2025 | n/a | n/a | -US$5b |
| Jun 30 2025 | n/a | n/a | US$2b |
| Mar 31 2025 | n/a | n/a | US$3b |
| Dec 31 2024 | US$21m | US$1m | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$3b |
| Dec 31 2023 | US$19m | US$1m | US$3b |
| Sep 30 2023 | n/a | n/a | US$2b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$13m | US$1m | US$1b |
| Sep 30 2022 | n/a | n/a | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$1b |
| Dec 31 2021 | US$15m | US$978k | US$1b |
Vergütung im Vergleich zum Markt: SarahDie Gesamtvergütung ($USD19.51M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.67M).
Entschädigung vs. Einkommen: SarahDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sarah London (45 yo)
4.3yrs
Amtszeit
US$19,506,298
Vergütung
Ms. Sarah M. London has been the Chief Executive Officer of Centene Corporation since March 21, 2022 and serves as its Director since September 2021. She served as President of Health Care Enterprises and...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$19.51m | 0.061% $ 18.8m | |
| Executive VP & CFO | 5.1yrs | US$16.07m | 0.061% $ 18.8m | |
| Chief Operating Officer | 2.4yrs | US$4.89m | 0.0063% $ 2.0m | |
| Executive VP | 6.3yrs | US$6.51m | 0.025% $ 7.7m | |
| Senior VP & Chief People Officer | 3.3yrs | US$3.17m | 0.0031% $ 957.7k | |
| Corporate Controller & Chief Accounting Officer | less than a year | keine Daten | 0.0025% $ 777.4k | |
| Chief Information Officer | 3.5yrs | keine Daten | keine Daten | |
| Senior Vice President of Investor Relations | 6.2yrs | keine Daten | keine Daten | |
| Chief Risk | 3.8yrs | keine Daten | keine Daten | |
| Executive VP & Chief of Staff | 22.4yrs | keine Daten | keine Daten | |
| President of Charitable Foundation | 6.3yrs | US$3.43m | keine Daten | |
| Executive Vice President of External Affairs | no data | keine Daten | keine Daten |
4.3yrs
Durchschnittliche Betriebszugehörigkeit
57yo
Durchschnittliches Alter
Erfahrenes Management: CNCDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$19.51m | 0.061% $ 18.8m | |
| Director | no data | keine Daten | keine Daten | |
| Independent Director | 3.6yrs | US$350.01k | 0.0022% $ 681.0k | |
| Independent Chairman | 20.2yrs | US$590.02k | 0.073% $ 22.8m | |
| Independent Director | 4.4yrs | US$370.01k | 0.0089% $ 2.8m | |
| Lead Independent Director | 6.4yrs | US$350.01k | 0.0092% $ 2.9m | |
| Independent Director | 4.4yrs | US$350.01k | 0.011% $ 3.3m | |
| Independent Director | 1.3yrs | US$397.11k | 0.0016% $ 497.5k | |
| Director | 4.4yrs | US$387.63k | 0.057% $ 17.6m | |
| Independent Director | 8.3yrs | US$370.01k | 0.0058% $ 1.8m |
4.4yrs
Durchschnittliche Betriebszugehörigkeit
67yo
Durchschnittliches Alter
Erfahrener Vorstand: CNCDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/25 21:59 |
| Aktienkurs zum Tagesende | 2026/06/25 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Centene Corporation wird von 32 Analysten beobachtet. 14 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |